

Flanders, a health(y) ecosystem

Cancer

Kathleen.dhondt@vlaanderen.be

a high-income region

FLANDERS: Key Figures report 2024

with an open economy in the core of Europe

■ Population: 6,77 million (= 58% BEL)

■ Language: Dutch (NL)

■ **Surface:** 13 521 km² (= 44% BEL)

■ GDP: € 296 billion (= 59%; BE € 502,3 bn)

Export : € 300 billion (BE € 370 bn)

■ GERD: € 10 816 billion (+/- 2/3 of BEL), of which € 7 896 billion BERD

■ Research intensity - % GERD/ GDP: 3,65% = 63% of BE R&D expenditure •

Total public budget STI policy: € 3 246 million, of which € 2 149 million R&D

The region has constitutional competences on research, innovation and economic policy


Flanders = "innovation leader" in RIS 2023

- 3RD BEST INNOVATIVE SYSTEM in the world (2020 ZEW innovationsindikator)
- 3RD IN EUROPE for innovative SMEs collaborating with others



Health(y) ecosystem Flanders





Participation in EU-projects

Mission Cancer

16 participations, 11,55 mio EUR EU-contribution Preferred partners IT, ES, DE, NL, FR

Success ratio

18,9% or 3,2% return, higher than expected based on population size

Horizon Europe Health research

7,5 mio EUR

Horizon Europe MSCA

2,02 mio EUR for Health research

Collaboration with other countries

Preferred partners IT, ES, DE, NL, FR, CH





KU Leuven/ UZ Leuven Leuven Kankerinstituut (LKI)

Facts & figures 2021

- > Cancer institute of
- •KU Leuven the most innovative university in Europe
- •UZ Leuven the largest university hospital in Belgium
- > 57.491 oncological consultations (UZ Leuven)
- > 1.591 peer-reviewed oncological publications



PARTICLE THERAPY INTERUNIVERSITY CENTER LEUVEN

COLLABORATION BETWEEN UZ LEUVEN • KU LEUVEN • CU SAINT-LUC • UCLOU' UZ GENT • CHU UCL NAMUR • UZ BRUSSEL • UZA

> 8 ongoing ERC grants

Protontherapie Particle

| Protontherapie | Protontherapie | Protontherapie | Voor patienten | Voor verwijzers | Voor ve

Protontherapy - Particle

Next-gen fluorescence imaging for research and theranostics

<u>Radiopharmaceutical Research</u>: specific PET tracers, performing experiments with radiotracers or implementing GMP compliant production of novel tracers for clinical application.

KU Leuven: 36,5 mio EUR Annual average budget in cancer research over the last 5 years

Cancer Research at Ughent / UZ Ghent CRIG

Covering fundamental, translational and clinical cancer research

From synthesis and delivery of anti-cancer drugs, over cancer cell profiling and imaging, in vitro and in vivo model systems, up to clinical cancer research.

Cancer research at CRIG covers the whole spectrum from bench to bedside.

Multidisciplinary research: different cancer types across expertise domains

Valorising and partnering with industry

CRIG 2023 in numbers




27,3 mio EUR Annual average budget in cancer research over the last 5 years



Plasma medicine -Plasma oncology University of Antwerp Using gas plasma for onco-immunotherapy

Various cancers: Melanoma, pancreatic cancer, glioblastoma, head & neck cancer,... In-vitroexperiments:3Dcancermodels(morerealistic)





Spheroids


Organoids patient-derived model

Modeling for better understanding

- Various plasma sources (+interaction liquid)
- •Interaction RONS+biomolecules



University of Antwerp CORE | Center for **Oncological Research**







VUB UZ Brussels ONCOLOGY RESEARCH CENTER (ORC)



Cell analysis

Genomics



Extended RNA Analysis (ERA) platform



Imaging technologies



New radiation techniques





Tumorbank



Proteomics

https://orc.vub.be/

7,7 mio EUR Annual average budget in cancer research over the last 5 years



Vanguard Initiative and the smart health pilot

Jolien Roovers - Co-coordinator of Vanguard Initiative Smart Health Pilot

Vanguard Initiative

39 of the most advanced industrial regions in Europe leading by example in delivering growth and jobs through industry-led interregional cooperation, co-creation, and co-investment



Learn

- Develop scoping note
- Mapping questionnaire
- •Identify lead regions and actions

Connect

- •Matching events for complementary partners
- Developing demonstration cases

Demonstrate

- Networked demonstration
- •Pilot lines and first of a kind factories
- •TRL 6-8

Commercialise


- •Launch of new ventures and start-ups
- New value chains
- •TRL9

Vanguard Initiative pilots



Vanguard Initiative Smart Health





- Flanders, South NL, East NL
- Emilia-Romagna, North-Est Romania, East & North Finland, Piedmont, Slovenia, Trento, Wallonia, Lombardy, Pays de la Loire, Saxony-Anhalt, Catalonia, (Wales)
- EIT Health
- Open for new regions

Bring regional ecosystems together

Boost implementation of personalised medicine and smart health across Europe


Investable interregional co-creation projects

More info on: https://www.s3vanguardinitiative.eu/pilots/smart-health

Objectives


Transform the connected European value chains on *Personalised Medicine (PM)* and smart health, by combining biomedical, technological and data-driven expertise.

Figure 2: Vanguard Initiative methodology




Source: Vanguard website

VI Smart Health Scope




Demo cases






TRACE MED - European interregional platform for new radiopharmaceuticals development in personalized medicine

- * To create an eco-system covering the entire value chain of the RP industry from research & development to production by breaking down existing silos and fostering coordination.
- To improve the management of the supply chain in RP by creating a network of complementary excellence service providers across Europe, ranging from research to industry.
- * To reduce the development process time by providing better connections between process phases.
- To facilitate the distribution/sale process of the ready-to-market molecule through the *already × established extensive distribution/sale networks of the partners.



Gateway tool – online matchmaking platform



The "VI Gateway" is Vanguard Initiative's B2B online matching tool for organisations based in any of our network's member regions. VI Gateway is currently serving the 4 VI Pilots listed below.

- 3DF
- ESM
- · Smart Health
- Al

Complementing the service portfolio of the VI Pilots with a 24/7 accessible online collaboration tool, VI Gateway allows organisations to share needs and promote services and expertise across borders, in order to facilitate direct matchmaking, innovation collaboration and support the deployment of innovation projects.



Via the VanguardInitiative website

➤ VI Pilots > The VI Gateway

Direct link:

https://gateway.s3vanguardinitiative.eu/

SUPPORTING INNOVATIVE SMES

With the aim to supporting innovative SMEs and knowledge institutes in particular, the VI Gateway is facilitating innovation collaboration between organisations active in the value chain of our Pilot Projects. VI Gateway allows its users to:

- · find new partners (end-users, technology provider, etc.)
- · facilitate matchmaking among organisations interested in a specific opportunity

VInnovate – interregional funding opportunity (TRL 6-8)



Funding & activities

- Grant. Funding rate to be checked at regional level
- Supporting TRLs 6-8 activities



Scope

- Solutions for twin transition or more autonomous industry
- Thematically linked to at least one VI Pilot



Consortia


- At least 2 organisations, from at least 2 VInnovate 2024 regions and 2 countries/states (i.e. international cooperation)
- At least 1 SME, in cooperation with other companies or research centres/universities



Range

- Total project costs: min. 100.000€
- Total project duration: max.
 36M

Thank you!



<u>Jolien.roovers@vlaanderen.be</u>

https://www.s3vanguardinitiative.eu/pilots/smarthealth-personalised-medicine LinkedIn



